In last trading session, Cognition Therapeutics Inc (NASDAQ:CGTX) saw 5.14 million shares changing hands with its beta currently measuring 0.89. Company’s recent per share price level of $0.68 trading at $0.06 or 10.28% at ring of the bell on the day assigns it a market valuation of $42.15M. That closing price of CGTX’s stock is at a discount of -273.53% from its 52-week high price of $2.54 and is indicating a premium of 67.65% from its 52-week low price of $0.22. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 33.4 million shares which gives us an average trading volume of 6.90 million if we extend that period to 3-months.
For Cognition Therapeutics Inc (CGTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Cognition Therapeutics Inc (NASDAQ:CGTX) trade information
Cognition Therapeutics Inc’s shares saw a change of -64.58% in year-to-date performance and have moved -2.82% in past 5-day. Cognition Therapeutics Inc (NASDAQ:CGTX) showed a performance of 111.18% in past 30-days. Number of shares sold short was 1.54 million shares which calculate 0.98 days to cover the short interests.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -16.44% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 52.62% while estimates for its earnings growth in next 5 years are of 32.88%.
Cognition Therapeutics Inc (NASDAQ:CGTX)’s Major holders
Insiders are in possession of 0.81% of company’s total shares while institution are holding 18.79 percent of that, with stock having share float percentage of 18.94%. Investors also watch the number of corporate investors in a company very closely, which is 18.79% institutions for Cognition Therapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at CGTX for having 1.15 million shares of worth $1.9 million. And as of 2024-06-30, it was holding 2.8644 of the company’s outstanding shares.
The second largest institutional holder is AWM INVESTMENT COMPANY, INC., which was holding about 0.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.6224 of outstanding shares, having a total worth of $1.08 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 1.01 shares of worth $0.69 million or 1.63% of the total outstanding shares. The later fund manager was in possession of 200.58 shares on Mar 31, 2025 , making its stake of worth around $0.14 million in the company or a holder of 0.32% of company’s stock.
